Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection.
Treatment of menorrhagia with levonorgestrel intrauterine system (LNG IUS) and transcervical resection. An open, therapeutic, randomized study. Central county hospital specializing in hysteroscopy. Two parallel groups of 30 subjects each. Thirty patients had a LNG IUS inserted within the first 7 days of menses; 29 patients underwent endometrial resection. A 12-month follow-up of menstrual blood loss and adverse events were evaluated. LNG IUS group: 13 patients reported one or more pelvic adverse events, bleeding disorders (n = 6), abdominal pain (n = 4), breast tenderness (n = 3), headache, acne (n = 2), and mood changes (n = 1). Six patients discontinued treatment because of irregular bleeding (n = 3), pain (n = 2), and acne (n = 1). In both groups, general feeling of genital health increased with Visual Analogue Scale score. Nine patients reported adverse events. This included pelvic pain indicating inflammation (n = 4), bleeding (n = 3), vaginitis (n = 1), and ulceration (n = 1). Treatment success at 12 months was achieved in 20 (67%) of the 30 patients in the LNG IUS group and in 26 (90%) of the 29 patients in the transcervical resection group. Adverse events were more often reported in the LNG IUS group. Both treatments effectively reduced the menstrual blood loss. Furthermore, the LNG IUS treatment is reversible and has no operative hazards.